SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent – Lotte Biologics, under the leadership of CEO Richard Lee, has once again made a notable appearance at the 42nd annual JPMorgan Healthcare Conference (JPMHC) on Tuesday.The JPMHC is ongoing in San Francisco from Monday to
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent –Flagship Pioneering, a company specializing in bioplatform innovation, and Samsung have announced a collaboration to enhance biopharmaceutical innovation on Monday. This partnership aims to utilize advanced technologies i
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent – The J.P. Morgan Healthcare Conference kicked off its 42nd annual conference at the Westin St. Francis San Francisco on Monday, with investors attending the event showing a lot of excitement about the prospect of a revita
Huons Meditech said it has obtained import approval for TULSA-PRO, a prostate cancer and benign prostatic hyperplasia treatment device, developed by Profound, a Canadian medical device company.TULSA-PRO is a treatment device based on ultrasound technology. The technology propagates through biologica
Dong-A ST said Accord Biopharma, a subsidiary of Intas Pharmaceutical, has received approval for the latter's biologics license application (BLA) for DMB-3115, a biosimilar referencing Stelara (ingredient: ustekinumab) to the FDA.Accord Biopharma had previously submitted the application to the FDA i
AstraZeneca Korea said that the Ministry of Food and Drug Safety (MFDS) approved Ultomiris (ingredient: ravulizumab) as an adjunct therapy for adults with antibody-positive acetylcholine receptor (AChR) generalized myasthenia gravis (gMG) on Thursday.Ultomiris had been approved for the treatment of
Korea recorded a trade deficit due to the global economic downturn in 2023, despite achieving the highest export volume in December.Notably, the biotech and healthcare industry, one of the five promising sectors, has experienced a continuous deficit for 16 months since July 2022.Despite an increase
GC Cell said that BioCentriq, its U.S. affiliate focused on cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), successfully raised a total of $29.2 million in a Series A funding.BioCentriq was acquired by GC Cell and Green Cross Holdings in 2022. The company, bas
Dong-A ST said it has signed a licensing agreement with SK biopharmaceuticals for the epilepsy drug cenobamate in 30 countries, including Korea, Southeast and Southwest Asia, Russia, Australia, New Zealand, and Turkey.The deal excludes the U.S. as cenobamate has been commercially available in the U.
Humasis, a medical diagnostics company, said on Wednesday that it filed a complaint with the Fair Trade Commission (FTC) against Celltrion, a biosimilar giant, for violating the Act on Fair Transactions in Subcontracting.The FTC filing comes after Humasis is undergoing a legal battle against Celltri
A Severance Hospital research team has newly identified a cause of retinoblastoma.Retinoblastoma is a white tumor that occurs in the retina and is the most common malignant tumor inside the eye of children. It can occur in one or both eyes. The most common symptom is a white pupil due to the tumor,
Korean pharmaceutical and biotech firms are set to participate in the upcoming J.P. Morgan Healthcare Conference, the world's largest healthcare conference known for capturing the interest of institutional investors. The event is scheduled to commence in San Francisco, the U.S., from Jan. 8-11.The c
Medytox, a Korean botulinum toxin (BTX) maker, said it has established a U.S. subsidiary Luvantas to advance into the global market with MT10109L, its non-animal-derived liquid BTX formulation.The company had submitted a biologics license application (BLA) for MT10109L to the FDA in late December. T
Helixmith said its gene therapy Engensis, also known as VM202-DPN, failed to meet the primary endpoint in a phase 3 clinical trial for treating diabetic peripheral neuropathy (DPN) conducted in the U.S.The phase 3 DPN trial was divided into two studies, 3-2 and 3-2b, where the primary endpoint invol
A research team at Severance Hospital found that exposure to antibiotics in patients with advanced gastric cancer diminishes the effectiveness of immunotherapy treatments.The incidence of gastric cancer is particularly high in Asia. In Korea, it was the fourth most common cancer in 2020, according t
Illumina, a pioneer in genomics, recently celebrated its 25th anniversary.Founded in 1998, Illumina has emerged as a pivotal force in global research for genomic research, delivering pioneering advancements that have reshaped the industry.The company's technologies have been cited in an impressive a
Qurient, a company specializing in developing anticancer drugs, has become the first to receive investment from the government-led K-Bio and Vaccine Fund.Qurient said the payment of 3.5 billion won ($2.7 million) in perpetual convertible bonds by the Premier IBK K-Bio Vaccine Investment Fund was com
The year 2023 marked significant transformations in the medical and pharmaceutical sectors. Despite facing resistance from the medical community, President Yoon Suk Yeol's administration declared its intention to increase the number of medical school seats starting in 2025. Additionally, 2023 witnes
The Celltrion Group announced the launch of the integrated entity of Celltrion and Celltrion Healthcare, in which Celltrion will be absorbing Celltrion Healthcare to form a single entity, on Thursday.The scheduled date for the listing of new shares resulting from this merger is Jan. 12, 2024, and se
Medytox said it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for MT10109L, a non-animal-derived liquid botulinum toxin (BTX) formulation indicated for improving moderate to severe frown lines and crow's feet.The submission follows Medytox's completion